Sanofi will acquire TargeGen for as much as $560 million

06/30/2010 | Reuters

Sanofi-Aventis agreed to pay as much as $560 million to acquire TargeGen, a San Diego developer of small-molecule kinase inhibitors designed to treat blood diseases, to boost its pipeline of cancer drugs. Sanofi will pay $75 million at the closing of the deal, which is expected this quarter.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL